| 1/3 | US=64 / Câncer Richardson PG, Mitsiades CS, Schlossman R, Hideshima T, Ghobrial I, Munshi NC, Anderson KC. The role of bortezomib in the treatment of relapsed and refractory multiple myeloma. In: Lonial S. Mylenoma therapy: pursuing the plasma cell. 5th ed. New Jersey: Humana Press, 2008. p. 239-52. (Comtemporary Hematology) ISBN 978-1-934115-82-4. |
| 2/3 | US=64 / Câncer San MFJ, Mateos MV. Bortezomib as induction therapy in patients with multiple myeloma. In: Lonial S. Mylenoma therapy: pursuing the plasma cell. 5th ed. New Jersey: Humana Press, 2008. p. 253-63. (Comtemporary Hematology) ISBN 978-1-934115-82-4. BORTEZOMIB; PACIENTES COM MIELOMA MULTIPLO. TERAPIA DE INDUCAO |
| 3/3 | Câncer Rodríguez MRL, Combariza J, Casas CP, Reveiz L, Buendía J, Carvajal AM, Ramírez HB, Cardona AF. First line therapy for patients with newly diagnosed multiple myeloma ineligible for autologous stem cell transplantation: a systematic review and meta-analysis (hemo-oncolgroup study). Applied Cancer Research, São Paulo: Tecmedd, v.32, n.4, p. 122-41, 2012. ISSN 1980-5578. Disponível em: http://accamargo.phlnet.com.br//applied/ACR2012;32(4)p.122-41.pdf QUIMIOTERAPIA; META-ANALISES; MIELOMA MULTIPLO; TRANSPLANTE AUTOLOGO |